180 Life Sciences Corp. announced the appointment of Quan A. Vu to the role of Chief Operating Officer/Chief Business Officer. Mr. Vu is a highly versatile and accomplished strategy, corporate/business development, finance and operations executive with 20 years of ?hands-on? biopharma experience. He is known as a consummate dealmaker with a demonstrated history of prospecting, evaluating, structuring and closing transactions that augment both organizational and shareholder value, as well as a persuasive negotiator who orchestrates domestic and international win-win solutions that integrate a diversity of views, expectations and goals. Prior to joining 180 Life Sciences, Mr. Vu served as a CBO/CFO consultant for LS Associates, a member company of LifeSci Partners, as well as a Managing Director and Co-Head of Healthcare IT at Solganick & Co., a boutique technology investment bank providing M&A advisory. He also served as CEO of Baleena Bioscience, a consolidator of several healthspan biotechnology/medical device assets with the express purpose of going public via a SPAC. Before the above roles, he held leadership positions of increasing responsibility at several companies, namely as a Vice President at Opiant Pharmaceuticals, Staff Vice President at Anthem, Director at Impax Laboratories and Senior Manager at Amgen. He began his career in financial and economic consulting at LECG and in healthcare corporate finance and M&A at bulge-bracket investment banks, including Morgan Stanley and Goldman Sachs. He graduated Summa Cum Laude with a Bachelor of Arts Economics from UCLA in 2000.